Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells.
By H. Mckenna, K. Stocking, Robert E. Miller, K. Brasel, T. de Smedt, E. Maraskovsky, C. Maliszewski, D. Lynch, Jeffrey Smith, Bali Pulendran and 4 more. Blood, 2000
999 citations recorded by the source corpus.
Subfields: Hematology, Immunology
View Paper: https://www.semanticscholar.org/paper/1a87ef44450504cea7b7529c5d2c6230ad774733
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Immunology
- Miriam Merad
- F. Geissmann
- C. Auffray
- Eric G. Pamer
- M. Sieweke
- A. Mortha
- Shalin H. Naik
- J. Villadangos
Citations in the corpus
- Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. (2002, neutral): “1); t(6;9)(p23;q34); der(7)t(7;13)(q32;q12), 13; t(9;15) (q22;q22); add(10)(q26); t(11;15)(p15;q11), t(12;20)(q21;?q12?3); t(11;20)(p15;q11); 20.”
- Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo (2007, background): “However Flt3 ligand (Flt3L), rather than granulocyte-macrophage colony-stimulating factor, is the limiting cytokine for the steady-state development of spleen DC”
- Cutting Edge: Generation of Splenic CD8+ and CD8− Dendritic Cell Equivalents in Fms-Like Tyrosine Kinase 3 Ligand Bone Marrow Cultures1 (2005, background): “The dependency on FL for DC generation in this culture system correlates with the observations that FL / mice have reduced DC numbers (11), that injection of mice with FL greatly increases DC numbers (12, 13), and that only early BM progenitors that express flt3 are effective precursors of DC (14).”
- The origin and development of nonlymphoid tissue CD103+ DCs (2009, neutral): “Flt3L/ mice (McKenna et al., 2000) were purchased from Taconic.”
- A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. (2004, neutral): “Median ECOG performance status, (range) 1 (1-3)”
- The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. (2013, background): “Similar to lymphoid tissue CD8+ cDCs, CD11b+ cDCs proliferate in situ in response to Flt3L, and are reduced in Flt3-and Flt3L-deficient mice, albeit to a lesser extent than CD8+ cDCs (25, 55).”
- Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes (2006, background): “However, the main cytokine driving the generation of steady-state cDC subtypes in vivo seems to be the ligand for the receptor tyrosine kinase Flt3 (refs”
- Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. (2005, background): “…for Flt3 in early lymphoid development has been further substantiated in studies of mice deficient in expression of Flt3 or its ligand, as these mice have reductions in early B and T cell progenitors as well as the CLPs (Mackarehtschian et al., 1995; McKenna et al., 2000; Sitnicka et al., 2002).”
- Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow (2007, background): “, and it supports the maintenance of DCs in steady-state lymphoid organs in vivo : Flt3L-deficient mice, mice with hematopoietic deletion of the gene encoding STAT3 (a transcription factor relevant in signaling 'downstream' of Flt3) and mice treated with Flt3 kinase inhibitors have about 10% the pD”